Year End Report 2014

Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Year End Report for 2014.

Financial Highlights

• Revenue for the 4th quarter 2014 was SEK 24.2 (22.8) million, and for the full year 57.6 (68.2) million
• Operating result for the period amounted to SEK 8.5 (1.7) million, and for the full year to 5.3 (8.5) million
• EBITDA for the period amounted to SEK 8.6 (1.8) million, and for the full year to 5.7 (8.7) million
• Net result for the period amounted to SEK 7.9 (0.9) million, and for the full year to 3.7 (6.6) million
• Cash flow for the period was SEK 9.9 (12.5) million, and for the full year 2.8 (11.8) million
• Cash and cash equivalents at the end of the period amounted to SEK 35.9 (33.1) million

Significant events during the quarter

• In October 2014, Sobi decided to place the phase 1 study of SOBI002 on clinical hold as adverse events were observed in the first-in-human study. All subjects that have been dosed with SOBI002 are well. Sobi is now working to understand these adverse events
• In November 2014 Nordic Nanovector ASA and Affibody AB announced that the companies have entered into a three-year collaborative research agreement to discover and develop new advanced radioimmunotherapies (RIT) for multiple myeloma, a collaboration backed by a Eurostars grant

Other significant events during 2014

• The first patient was included in a PET Imaging Study of HER2 Expression in Breast Cancer at Herlev University Hospital
• Investor AB acquired all HealthCap’s shares in Affibody

Significant events after the end of the reporting period

• No significant events were reported after the end of the reporting period